Diffuse large B-cell lymphoma
M Martelli, AJM Ferreri, C Agostinelli, A Di Rocco… - Critical reviews in …, 2013 - Elsevier
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults
accounting for 31% of all NHL in Western Countries. Following, morphological, biological …
accounting for 31% of all NHL in Western Countries. Following, morphological, biological …
Overview of lymphoma diagnosis and management
MJ Matasar, AD Zelenetz - Radiologic Clinics of North America, 2008 - Elsevier
The malignant lymphomas, including both Hodgkin lymphoma (HL) and non-Hodgkin
lymphoma (NHL), represent a diverse group of diseases that arise from a clonal proliferation …
lymphoma (NHL), represent a diverse group of diseases that arise from a clonal proliferation …
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009
Abstract The European Group for Blood and Marrow Transplantation regularly publishes
special reports on the current practice of haematopoietic SCT for haematological diseases …
special reports on the current practice of haematopoietic SCT for haematological diseases …
Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP
P Pregno, A Chiappella, M Bellò, B Botto… - Blood, The Journal …, 2012 - ashpublications.org
Role of interim-PET (I-PET) in diffuse large B-cell Lymphoma (DLBCL) is controversial. To
determine predictive value of I-PET on progression-free survival (PFS), we enrolled 88 first …
determine predictive value of I-PET on progression-free survival (PFS), we enrolled 88 first …
[HTML][HTML] Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma
B Sirohi, D Cunningham, R Powles, F Murphy… - Annals of …, 2008 - Elsevier
Background The purpose of this study was to assess prognostic factors and outcome of
patients with relapsed/refractory Hodgkin's lymphoma (HL) who received high-dose …
patients with relapsed/refractory Hodgkin's lymphoma (HL) who received high-dose …
[HTML][HTML] Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 …
H Holte, S Leppä, M Björkholm, Ø Fluge, S Jyrkkiö… - Annals of oncology, 2013 - Elsevier
Background Many patients with aggressive B-cell lymphomas and high clinical risk score
still die of lymphoma after conventional R-CHOP chemoimmunotherapy. We hypothesized …
still die of lymphoma after conventional R-CHOP chemoimmunotherapy. We hypothesized …
Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas
Purpose The benefit of high-dose chemotherapy with autologous stem-cell transplantation
(ASCT) as first-line treatment in patients with diffuse large B-cell lymphomas is still a matter …
(ASCT) as first-line treatment in patients with diffuse large B-cell lymphomas is still a matter …
High‐dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non‐Hodgkin lymphoma (NHL) in adults
A Greb, J Bohlius, D Schiefer… - Cochrane Database …, 2008 - cochranelibrary.com
Background High‐dose chemotherapy with autologous stem cell support (HDT) has been
proven effective in relapsed aggressive non‐Hodgkin lymphoma (NHL). However …
proven effective in relapsed aggressive non‐Hodgkin lymphoma (NHL). However …
Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma
C Hosing, RM Saliba, S Ahlawat… - American journal of …, 2009 - Wiley Online Library
The purpose of this retrospective study was to determine the incidence and predictive factors
if any, of mobilization failure in lymphoma patients referred for autologous stem cell …
if any, of mobilization failure in lymphoma patients referred for autologous stem cell …
[HTML][HTML] The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based …
DM Oliansky, M Czuczman, RI Fisher, FD Irwin… - Biology of blood and …, 2011 - Elsevier
Clinical research published since the 2001 evidence-based review on the role of
hematopoietic stem cell transplantation (SCT) in the treatment of diffuse large B cell …
hematopoietic stem cell transplantation (SCT) in the treatment of diffuse large B cell …